インスリン抵抗治療薬の世界市場2022

【英語タイトル】Insulin Resistance Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Global Markets Directが出版した調査資料(GMDHC22069IDB)・商品コード:GMDHC22069IDB
・発行会社(調査会社):Global Markets Direct
・発行日:2022年3月
・ページ数:38
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥296,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥592,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD6,000 ⇒換算¥888,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートでは、開発中のインスリン抵抗治療薬市場について調査・分析し、インスリン抵抗概要、治療薬開発、パイプライン概要、企業別のパイプライン、企業別の開発中製品、治療薬分析、標的別分析、作用機序別分析、投与経路別分析、分子タイプ別分析、治療薬開発に携わる企業など、以下の項目を掲載しております。
・インスリン抵抗-概要
・インスリン抵抗-治療薬開発
・パイプライン概要
・企業別のパイプライン
・企業別の開発中製品
・インスリン抵抗-治療薬分析
・標的別分析
・作用機序別分析
・投与経路別分析
・分子タイプ別分析
・インスリン抵抗-治療薬開発に携わる企業
【レポートの概要】

Insulin Resistance Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Insulin Resistance – Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Insulin Resistance (Metabolic Disorders) pipeline landscape.

Insulin resistance (IR) is a condition in which the body’s cells become resistant to the effects of insulin. This occurs when insulin levels are sufficiently high over a prolonged period of time causing the body’s own sensitivity to the hormone to be reduced. Symptoms include lethargy, hunger, difficulty concentrating and high blood pressure. Predisposing factors include obesity and hypertension.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Insulin Resistance – Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Insulin Resistance (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Insulin Resistance (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Insulin Resistance and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 9 and 1 respectively.

Insulin Resistance (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Insulin Resistance (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Insulin Resistance (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Insulin Resistance (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Insulin Resistance (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Insulin Resistance (Metabolic Disorders)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Insulin Resistance (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Insulin Resistance (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Insulin Resistance – Overview
Insulin Resistance – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Insulin Resistance – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Insulin Resistance – Companies Involved in Therapeutics Development
Amolyt Pharma
Amryt Pharma Plc
CohBar Inc
Exscien Corp
Glycomantra Inc
Hanmi Pharmaceuticals Co Ltd
Lixte Biotechnology Holdings Inc
NorthSea Therapeutics BV
The Healthy Aging Co
Trigemina Inc
Insulin Resistance – Drug Profiles
ALF-5755 – Drug Profile
Product Description
Mechanism Of Action
AZP-3404 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Fusion Protein to Target hOGG1 for Acute Lung Injury and Insulin Resistance – Drug Profile
Product Description
Mechanism Of Action
History of Events
HM-15136 – Drug Profile
Product Description
Mechanism Of Action
icosabutate – Drug Profile
Product Description
Mechanism Of Action
History of Events
LB-100 – Drug Profile
Product Description
Mechanism Of Action
History of Events
metreleptin – Drug Profile
Product Description
Mechanism Of Action
History of Events
MOTS-c – Drug Profile
Product Description
Mechanism Of Action
History of Events
oxytocin – Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Immunology, Insulin Resistance and Musculoskeletal Disorders – Drug Profile
Product Description
Mechanism Of Action
History of Events
TFD-100 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Insulin Resistance – Dormant Projects
Insulin Resistance – Product Development Milestones
Featured News & Press Releases
Mar 21, 2019: Alize Pharma3 to present data from its AZP-3404program in syndromes of severe insulin resistance at ENDO2019
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Insulin Resistance, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Insulin Resistance - Pipeline by Amolyt Pharma, 2022
Insulin Resistance - Pipeline by Amryt Pharma Plc, 2022
Insulin Resistance - Pipeline by CohBar Inc, 2022
Insulin Resistance - Pipeline by Exscien Corp, 2022
Insulin Resistance - Pipeline by Glycomantra Inc, 2022
Insulin Resistance - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
Insulin Resistance - Pipeline by Lixte Biotechnology Holdings Inc, 2022
Insulin Resistance - Pipeline by NorthSea Therapeutics BV, 2022
Insulin Resistance - Pipeline by The Healthy Aging Co, 2022
Insulin Resistance - Pipeline by Trigemina Inc, 2022
Insulin Resistance - Dormant Projects, 2022
Insulin Resistance - Dormant Projects, 2022 (Contd..1)

List of Figures
Number of Products under Development for Insulin Resistance, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

★調査レポート[インスリン抵抗治療薬の世界市場2022] (コード:GMDHC22069IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[インスリン抵抗治療薬の世界市場2022]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆